These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 12188326)

  • 1. MRI monitoring of tumor response to a novel VEGF tyrosine kinase inhibitor in an experimental breast cancer model.
    Turetschek K; Preda A; Floyd E; Shames DM; Novikov V; Roberts TP; Wood JM; Fu Y; Carter WO; Brasch RC
    Acad Radiol; 2002 Aug; 9 Suppl 2():S519-20. PubMed ID: 12188326
    [No Abstract]   [Full Text] [Related]  

  • 2. Tumor microvascular changes to anti-angiogenic treatment assessed by MR contrast media of different molecular weights.
    Roberts TP; Turetschek K; Preda A; Novikov V; Moeglich M; Shames DM; Brasch RC; Weinmann HJ
    Acad Radiol; 2002 Aug; 9 Suppl 2():S511-3. PubMed ID: 12188324
    [No Abstract]   [Full Text] [Related]  

  • 3. Vascular endothelial growth factor-A determines detectability of experimental melanoma brain metastasis in GD-DTPA-enhanced MRI.
    Leenders W; Küsters B; Pikkemaat J; Wesseling P; Ruiter D; Heerschap A; Barentsz J; de Waal RM
    Int J Cancer; 2003 Jul; 105(4):437-43. PubMed ID: 12712432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
    Yano S; Herbst RS; Shinohara H; Knighton B; Bucana CD; Killion JJ; Wood J; Fidler IJ
    Clin Cancer Res; 2000 Mar; 6(3):957-65. PubMed ID: 10741721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM
    Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
    Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High resolution MRI of MCF7 human breast tumors: complemented use of iron oxide microspheres and Gd-DTPA.
    Furman-Haran E; Margalit R; Grobgeld D; Degani H
    J Magn Reson Imaging; 1998; 8(3):634-41. PubMed ID: 9626879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor microvascular characterization using ultrasmall superparamagnetic iron oxide particles (USPIO) in an experimental breast cancer model.
    Turetschek K; Roberts TP; Floyd E; Preda A; Novikov V; Shames DM; Carter WO; Brasch RC
    J Magn Reson Imaging; 2001 Jun; 13(6):882-8. PubMed ID: 11382948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamic MRI enhanced with albumin-(Gd-DTPA)30 or ultrasmall superparamagnetic iron oxide particles (NC100150 injection) for the measurement of microvessel permeability in experimental breast tumors.
    Turetschek K; Huber S; Helbich T; Floyd E; Tarlo KS; Roberts TP; Shames DM; Wendland MF; Brasch RC
    Acad Radiol; 2002 May; 9 Suppl 1():S112-4. PubMed ID: 12019843
    [No Abstract]   [Full Text] [Related]  

  • 10. Hepatocyte growth factor/scatter factor can induce angiogenesis independently of vascular endothelial growth factor.
    Sengupta S; Gherardi E; Sellers LA; Wood JM; Sasisekharan R; Fan TP
    Arterioscler Thromb Vasc Biol; 2003 Jan; 23(1):69-75. PubMed ID: 12524227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
    Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS
    J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MR imaging characterization of microvessels in experimental breast tumors by using a particulate contrast agent with histopathologic correlation.
    Turetschek K; Huber S; Floyd E; Helbich T; Roberts TP; Shames DM; Tarlo KS; Wendland MF; Brasch RC
    Radiology; 2001 Feb; 218(2):562-9. PubMed ID: 11161179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584.
    Thomas AL; Morgan B; Drevs J; Unger C; Wiedenmann B; Vanhoefer U; Laurent D; Dugan M; Steward WP
    Semin Oncol; 2003 Jun; 30(3 Suppl 6):32-8. PubMed ID: 12802793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The potential value of iron oxide nanoparticles in brain tumor treatment.
    Gutin PH
    AJNR Am J Neuroradiol; 2002 Apr; 23(4):505. PubMed ID: 11950633
    [No Abstract]   [Full Text] [Related]  

  • 15. Quantitative assessment of the contrast behavior of typical focal hepatic lesions before and after the administration of Gd-DTPA and superparamagnetic iron oxide particles.
    Helmberger T; Holzknecht N; Reiser M
    Acad Radiol; 2002 Aug; 9 Suppl 2():S468-72. PubMed ID: 12188311
    [No Abstract]   [Full Text] [Related]  

  • 16. Magnetic resonance macromolecular agents for monitoring tumor microvessels and angiogenesis inhibition.
    Preda A; van Vliet M; Krestin GP; Brasch RC; van Dijke CF
    Invest Radiol; 2006 Mar; 41(3):325-31. PubMed ID: 16481916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A mycobacterial iron chelator, desferri-exochelin, induces hypoxia-inducible factors 1 and 2, NIP3, and vascular endothelial growth factor in cancer cell lines.
    Chong TW; Horwitz LD; Moore JW; Sowter HM; Harris AL
    Cancer Res; 2002 Dec; 62(23):6924-7. PubMed ID: 12460908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing perfusion and capillary permeability changes induced by a VEGF inhibitor in human tumor xenografts using macromolecular MR imaging contrast media.
    Clément O; Pradel C; Siauve N; Frouin F; Bruneteau G; Kahn E; Frija G; Cuénod CA
    Acad Radiol; 2002 Aug; 9 Suppl 2():S328-9. PubMed ID: 12188264
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and safety of liver-specific MRI contrast agents in rats with hepatitis and cirrhosis.
    Kato N; Takahashi M; Ihara S; Tsujimoto T; Miyazawa T
    Acad Radiol; 1998 Apr; 5 Suppl 1():S83-5. PubMed ID: 9561051
    [No Abstract]   [Full Text] [Related]  

  • 20. Use of intravascular contrast agents in MRI.
    Bjørnerud A; Wendland MF; Johansson L; Ahlstrom HK; Higgins CB; Oksendal A
    Acad Radiol; 1998 Apr; 5 Suppl 1():S223-5. PubMed ID: 9561086
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.